Regarding the optimization of PCa patient-specific treatment options after surgery, the culturing and PCSC analysis of NF-κB induction potency may improve supportive therapies, such as TNF-inducing chemotherapeutics and/or NF-κB inhibitors. This evidence concerns the gene NFKB1 and posterior cortical atrophy.